AbbVie, Bristol-Myers, Pfizer, Roche sales and marketing update

Late last year, the U.K.’s NICE issued final guidance recommending four DMARDs to treat juvenile idiopathic arthritis -- their approved indication. The final guidance is in line with the final draft guidance, which stated that when more than one drug is suitable, treatment should be started with the least expensive option. The drugs are Enbrel etanercept from Pfizer, Humira adalimumab from AbbVie, Orencia abatacept from Bristol-Myers Squibb and RoActemra tocilizumab from Roche. ...